© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2017
Community Voices Enrich the International Liver Congress
Click Here for EASL.eu
An Introduction to Hepatitis

Conferences

EASL 2017 Roundup: Continued Progress in Fighting Liver Disease

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Older People Who Cleared Hepatitis B Still Have Raised Risk of Liver Cancer

This is particularly true among men older than 50, who warrant greater monitoring.

Curing Hepatitis C Can Get People Off the Liver Transplant List

This holds true even for those with highly severe liver disease.

Merck’s Triple-Drug Hep C Combo Cures Almost All of Retreated Group

The trial tested 16 and 24 weeks of grazoprevir/uprifosbuvir/ruzasvir among those with genotype 1 who had failed a previous treatment.

Treating Liver Cancer With Radioactive Beads Improves Quality of Life

Compared with the standard treatment, this new method also appears to be safer—but it doesn’t offer a longer life.

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
NASH: The Basics

Generic Versions of Major Hepatitis C Drugs Prove Highly Effective

Some countries, such as Australia and the United Kingdom, permit people to import generic drugs for personal use.

Gilead’s NASH Drug Shows Promise in Early Trial

A small proof-of-concept study of GS-0976 inhibited de novo lipogenesis (DNL) and reduced liver fat and stiffness.

Reconfigured Version of NASH Drug FGF21 Improves Liver Health

BMS-986036, a retooled version of the non-alcoholic steatohepatitis drug FGF21, showed promise in a Phase II trial.

Liver Fat Isn’t the True Culprit Behind NASH-Related Disease Progression

The actual cause was discovered during the failed trial of a non-alcoholic steatohepatitis (NASH) treatment.

Modified Version of NASH Drug That Was Linked to Cancer Now Shows Promise

Researchers retooled the non-alcoholic steatohepatitis treatment FGF19 to yield a variant dubbed NGM282.

Hot topics

Forums: Support and discussion
Blogs: The community speaks

In Those With Cirrhosis, Severe Gum Disease Is Tied With Raised Risk of Death

The risk for death from cirrhosis itself is particularly high.

Global Viral Hepatitis Death Rate Rivals TB and HIV

A new World Health Organization (WHO) report is the most definitive account to date of the global impact of hepatitis B and C.

Curing Hepatitis Cuts the Risk of Cardiovascular Disease

Among people with hep C and compensated cirrhosis, this risk reduction was particularly stark after six years of follow-up.

Janssen/Achillion’s Triple-Drug Hep C Regimen Cures All Those With Genotype 1

The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.

Eight Weeks of AbbVie’s G/P Cures Almost All Those With Genotype 3 of Hep C

The investigational glecaprevir/pibrentasvir was tested among people with genotype 3 of hepatitis C virus who did not have cirrhosis.
Advertisement
Science News
Newsfeed
Features
Ask Hep

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.